 |
 |
From: Brian Druker Sent: Thursday, October 22, 2015 9:43 PM To: Rayilyn Brown Subject: RE: cost of nilotinib Dear Rayilyn, Yes, I did see the dramatic and promising results of nilotinib for Parkinson’s. If the drug is approved for Parkinson’s disease after additional clinical trials are conducted, then insurance should cover the bulk of the cost of the drug and during the clinical trials, the drug company would pay for the cost of the drug. I am not sure who best to contact at Novartis, but might start with August Salvado ([log in to unmask]). He is the VP for Early Development. I did not receive NIH funds to develop these drugs, but was funded by the Leukemia & Lymphoma Society. Best, Brian Druker, MD From: Rayilyn Brown [mailto:[log in to unmask]] Sent: Monday, October 19, 2015 2:36 PM To: Brian Druker Cc: Ming-Jai Liu; Shirley S Knox; parkinsn Subject: cost of nilotinib Dr. Druker: I just learned about the dramatic and promising results of your cancer drug for Parkinson’s patients. My retiree teacher’s pension is under $30,000 a year and I can’t afford the $120,000 yearly cost. Could you possibly tell me who can contact at Novartis on behalf of millions of Parkinson disease patients who might be helped by this drug if they could afford it? Am I correct that you received a NIH grant to develop this drug? I’m an ovarian cancer survivor and really appreciate what you have done. thank you so much. Rayilyn Brown Past Director AZNPF Arizona Chapter National Parkinson Foundation ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn